BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment


You May Also Like

Medtronic Announces Japanese Regulatory Approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon

Clinically-Proven, Durable, Consistent, and Safe Market-Leading DCB Poised to Improve Outcomes for PAD Patients ...

Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors

HOUSTON, July 17, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company ...